A common diabetes drug may help slow age-related vision loss, giving researchers a promising new clue for protecting eyesight ...

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—a type of ...

Researchers published findings on June 3, 2026, describing an oral pill that burns fat by targeting skeletal muscle and brown ...

A study on over 800k adults with type 2 diabetes found that semaglutide and other GLP-1 drugs did not increase or decrease ...

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of ...

Experts at the 20th Annual Diabetes Conference say new medications are improving treatment, but diabetes and obesity continue ...

The NHS begins offering teplizumab, the first drug shown to delay type 1 diabetes and postpone insulin by nearly three years.

Add Yahoo as a preferred source to see more of our stories on Google. According to the WHO, more than 800 million people around the world have diabetes, with more than half of them not receiving ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors—such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)—or ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and fenofibrates are associated with a reduced risk for diabetic macular edema (DME) in patients with type 2 diabetes, while calcium channel ...

The search for effective dementia prevention continues to challenge medical researchers worldwide. Now, a major study published in JAMA Neurology reveals that certain medications used to treat type 2 ...